NCT02362711View on ClinicalTrials.gov

Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea

PHASE3CompletedINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 28, 2017

Conditions
Dysmenorrhea
Interventions
DRUG

NPC-16 Standard Dosing Regimen Group

DRUG

NPC-16 Continuous Dosing Regimen Group

DRUG

Placebo Group

Sponsors

Lead Sponsor

Nobelpharma
All Listed Sponsors
lead

Nobelpharma

INDUSTRY

NCT02362711 - Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea | Biotech Hunter | Biotech Hunter